Related Experiment Video
Updated: Aug 3, 2025

Analysis of DNA Double-strand Break DSB Repair in Mammalian Cells
Published on: September 8, 2010
The APE2 nuclease is essential for DNA double-strand break repair by microhomology-mediated end joining
Hubert Fleury1, Myles K MacEachern1, Clara M Stiefel2
1Department of Molecular, Cellular & Developmental Biology, University of Colorado Boulder, Boulder, CO, USA.
Abstract:
Microhomology-mediated end joining (MMEJ) is an intrinsically mutagenic pathway of DNA double-strand break (DSB) repair essential for proliferation of homologous recombination (HR)-deficient tumors. Although targeting MMEJ has emerged as a powerful strategy to eliminate HR-deficient (HRD) cancers, this is limited by an incomplete understanding of the mechanism and factors required for MMEJ repair. Here, we identify the APE2 nuclease as an MMEJ effector. We show that loss of APE2 inhibits MMEJ at deprotected telomeres and at intra-chromosomal DSBs and is epistatic with Pol Theta for MMEJ activity. Mechanistically, we demonstrate that APE2 possesses intrinsic flap-cleaving activity, that its MMEJ function in cells depends on its nuclease activity, and further identify an uncharacterized domain required for its recruitment to DSBs. We conclude that this previously unappreciated role of APE2 in MMEJ contributes to the addiction of HRD cells to APE2, which could be exploited in the treatment of cancer.
Insights
The APE2 nuclease is crucial for microhomology-mediated end joining (MMEJ) DNA repair in cancer cells. Targeting APE2 could offer a new strategy for treating homologous recombination-deficient cancers.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Microhomology-mediated end joining (MMEJ) is a DNA double-strand break (DSB) repair pathway.
- MMEJ is essential for the proliferation of homologous recombination-deficient (HRD) tumors.
- Targeting MMEJ is a promising strategy for eliminating HRD cancers, but requires a deeper understanding of the pathway.
Purpose of the Study:
- To identify novel factors involved in MMEJ repair.
- To elucidate the mechanism by which APE2 functions in MMEJ.
- To explore the therapeutic potential of targeting APE2 in HRD cancers.
Main Methods:
- Investigated the role of APE2 nuclease in MMEJ using cellular assays.
- Assessed MMEJ inhibition in cells lacking APE2 at telomeres and chromosomal breaks.
- Determined the epistatic relationship between APE2 and Pol Theta in MMEJ.
- Characterized APE2's flap-cleaving activity and its dependence on nuclease activity for MMEJ.
- Identified a novel domain in APE2 required for its recruitment to DSBs.
Main Results:
- APE2 nuclease was identified as a key effector of MMEJ.
- Loss of APE2 significantly inhibited MMEJ at deprotected telomeres and intra-chromosomal DSBs.
- APE2 function in MMEJ was found to be epistatic with Pol Theta.
- APE2 exhibits intrinsic flap-cleaving activity essential for its MMEJ role.
- A previously uncharacterized domain of APE2 is required for its recruitment to DSBs.
Conclusions:
- APE2 plays a critical, previously unrecognized role in MMEJ.
- HRD cells are dependent on APE2 for MMEJ repair.
- APE2's function in MMEJ presents a potential therapeutic vulnerability in HRD cancers.
More Related Videos
Related Concept Videos
Homologous Recombination
Fixing Double-strand Breaks
Nucleotide Excision Repair
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Long-patch Base Excision Repair
Base Excision Repair
The first step of...

